BLC
DGX icon

Brown, Lisle/Cummings’s Quest Diagnostics DGX Stock Holding History

Brown, Lisle/Cummings’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.15K Buy
29
+18
+164% +$3.53K ﹤0.01% 677
2026
Q1 		$2.16K Buy
+11
New +$2.14K ﹤0.01% 799

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Brown, Lisle/Cummings's DGX Position: Q2 2026 in Review

Brown, Lisle/Cummings increased its Quest Diagnostics (DGX) stake by 164% in Q2 2026, buying an estimated $3.53K and bringing the position to 29 shares worth $6.15K. The position accounts for ﹤0.01% of the portfolio, ranked #677.

Brown, Lisle/Cummings first reported a position in DGX in Q1 2026 and has held it in 2 quarters since. 1,111 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Brown, Lisle/Cummings held 29 shares of Quest Diagnostics worth $6.15K as of Q2 2026.
  • Brown, Lisle/Cummings bought 18 Quest Diagnostics shares in Q2 2026, an estimated $3.53K.
  • Quest Diagnostics made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #677 holding.
  • Brown, Lisle/Cummings first reported a position in Quest Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • 1,111 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.